<DOC>
	<DOCNO>NCT00000791</DOCNO>
	<brief_summary>To determine safety anti-HIV activity two dose SC-49483 combination zidovudine ( AZT ) versus AZT alone . To determine influence viral phenotype anti-HIV activity treatment regimen . SC-49483 inherent activity HIV-1 convert intestinal wall SC-48334 , demonstrate anti-HIV activity . Since SC-49483 cause significantly less gastrointestinal toxicity SC-48334 , combination SC-49483 AZT may improve benefit drug patient HIV infection .</brief_summary>
	<brief_title>A Phase II Double-Blind Study Two Doses SC-49483 Combination With Zidovudine ( ZDV ) Versus ZDV</brief_title>
	<detailed_description>SC-49483 inherent activity HIV-1 convert intestinal wall SC-48334 , demonstrate anti-HIV activity . Since SC-49483 cause significantly less gastrointestinal toxicity SC-48334 , combination SC-49483 AZT may improve benefit drug patient HIV infection . Patients randomize receive AZT alone combination one two dose SC-49483 , administer three time daily . Treatment continue 16 24 week . Per 07/19/94 amendment : At end 24 week , blind treatment continue additional 4 week , time patient may receive open-label drug optional basis 90 day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis ( trimethoprim/sulfamethoxazole , dapsone , aerosolized pentamidine ) patient CD4 count &lt; = 200 cells/mm3 . Allowed : Topical antifungal agent , ketoconazole , fluconazole , itraconazole candidiasis disseminate fungal infection , medically indicate . Maintenance therapy Mycobacteria disease isoniazid , ethambutol , rifampin , pyrazinamide , clofazimine , ciprofloxacin , clarithromycin , rifabutin . Maintenance therapy toxoplasmosis pyrimethamine , sulfadiazine , clindamycin . Maintenance therapy herpes simplex virus acyclovir &lt; = 1000 mg/day . Recombinant erythropoietin GCSF , indicate . Antibiotics bacterial infection . Symptomatic treatment antipyretic , analgesic , nonsteroidal antiinflammatory agent , antiemetic . Concurrent Treatment : Allowed : Localized radiation therapy limit intralesional therapy cutaneous Kaposi 's sarcoma . Patients must : Documented HIV infection . Per 07/19/94 amendment , one following : CD4 count 150 350 cells/mm3 within 60 day prior study entry AND prior AZT 12 month cumulative ( give without ddI ddC ) . CD4 count 50 350 cells/mm3 within 60 day prior study entry AND prior antiretroviral therapy . MT2 cell assay within 60 day prior study entry . NOTE : Minimal Kaposi 's sarcoma permit . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Malignancy minimal Kaposi 's sarcoma . Concurrent Medication : Excluded : Antiretroviral therapy ( study drug ) . Biologic response modifier . Systemic corticosteroid &gt; 21 consecutive day . Foscarnet . Systemic cytotoxic chemotherapy malignancy . Patients follow prior condition exclude : History cataract . History intolerance AZT &lt; = 600 mg/day . Unexplained temperature &gt; = 38.5 degree C persist 7 day within 30 day prior study entry . Chronic diarrhea ( define &gt; = 3 stool per day ) persist 15 day within 30 day prior study entry . Prior Medication : Excluded : More 6 month ( 12 month per 07/19/94 amendment ) cumulative prior therapy AZT . Prior induction maintenance therapy foscarnet . Any investigational drug within 30 day prior study entry . Prior SC49483 SC48334 . Prior ddC , ddI , stavudine ( d4T ) monotherapy . Interferon interleukin within 30 day prior study entry . Prior nonnucleoside reverse transcriptase inhibitor ( e.g. , NVP , ATV ) . Systemic corticosteroid &gt; 21 consecutive day . Acute treatment serious infection opportunistic infection within 14 day prior study entry . Prior combination therapy AZT , ddI , and/or ddC within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>